| __timestamp | Gilead Sciences, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2854000000 | 46425000 |
| Thursday, January 1, 2015 | 3014000000 | 81491000 |
| Friday, January 1, 2016 | 5098000000 | 94291000 |
| Sunday, January 1, 2017 | 3734000000 | 121827000 |
| Monday, January 1, 2018 | 5018000000 | 160524000 |
| Tuesday, January 1, 2019 | 9106000000 | 200000000 |
| Wednesday, January 1, 2020 | 5039000000 | 275000000 |
| Friday, January 1, 2021 | 5363000000 | 328100000 |
| Saturday, January 1, 2022 | 4977000000 | 463800000 |
| Sunday, January 1, 2023 | 6923000000 | 565000000 |
| Monday, January 1, 2024 | 5907000000 | 731100000 |
Cracking the code
In the ever-evolving landscape of biotechnology, research and development (R&D) investments are pivotal for innovation and growth. Over the past decade, Gilead Sciences, Inc. and Neurocrine Biosciences, Inc. have demonstrated contrasting yet intriguing R&D investment strategies.
Gilead Sciences, a leader in antiviral drugs, has consistently invested heavily in R&D, with expenditures peaking in 2019 at nearly 9 billion USD. This represents a staggering 219% increase from 2014, underscoring their commitment to pioneering treatments. In contrast, Neurocrine Biosciences, known for its focus on neurological and endocrine disorders, has shown a steady increase in R&D spending, culminating in a 2023 investment of approximately 565 million USD, a twelvefold rise since 2014.
These investment trends highlight the strategic priorities of each company, with Gilead's aggressive approach contrasting with Neurocrine's steady growth, reflecting their respective market positions and innovation goals.
AbbVie Inc. or Gilead Sciences, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Novartis AG and Gilead Sciences, Inc.
R&D Insights: How Gilead Sciences, Inc. and Axsome Therapeutics, Inc. Allocate Funds
Comparing Innovation Spending: Gilead Sciences, Inc. and Catalyst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Gilead Sciences, Inc. vs Perrigo Company plc
Comparing Innovation Spending: Gilead Sciences, Inc. and Novavax, Inc.
Analyzing R&D Budgets: GSK plc vs Neurocrine Biosciences, Inc.
R&D Insights: How Teva Pharmaceutical Industries Limited and Neurocrine Biosciences, Inc. Allocate Funds
Comparing Innovation Spending: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Veracyte, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Xencor, Inc.